FrancophonIA/ELRC3.0 huggingface dataset:
English: Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first.
Croatian: Unutar svake klasifikacije organskog sustava nuspojave su poredane po učestalosti, pri čemu su najučestalije nuspojave navedene prve.
English: Take the box containing the syringe out of the refrigerator and leave it unopened for about 15-30 minutes so that it reaches room temperature.
Croatian: Uzmite kutiju koja sadrži štrcaljku iz hladnjaka i ostavite je neotvorenu oko 15-30 minuta kako bi dosegla sobnu temperaturu.
English: The co-primary endpoints in the placebo and active-controlled studies were the proportion of patients who achieved a PASI 75 response and IGA mod 2011 “clear” or “almost clear” response versus placebo at week 12 (see Tables 2 and 3).
Croatian: Mjere ko-primarnog ishoda u placebom i aktivno kontroliranim ispitivanjima bile su udjeli bolesnika koji su postigli odgovor PASI 75 i IGA mod 2011 odgovor „čista“ ili „gotovo čista“ u usporedbi s placebom u 12. tjednu (vidjeti Tablice 2 i 3).
English: Week 52 Placebo 150 mg 300 mg Etanercept 150 mg 300 mg Etanercept 150 mg 300 mg Etanercept
Croatian: 52. tjedan Placebo 150 mg 300 mg Etanercept 150 mg 300 mg Etanercept 150 mg 300 mg Etanercept
English: Based on clinical response, the dose can be increased to 300 mg.
Croatian: Na temelju kliničkog odgovora doza se može povećati na 300 mg.
English: Figure 1 Time course of percentage change from baseline of mean PASI score in study 1 (ERASURE)
Croatian: Slika 1 Vremenski tijek promjene srednje vrijednosti PASI-ja u postotku u odnosu na početnu vrijednost u 1. ispitivanju (ERASURE)
English: The solution should be administered within one hour after removal from 2°C to 8°C storage.
Croatian: Otopinu treba primijeniti u roku od sat vremena nakon što se makne s temperature od 2 °C do 8 °C.
English: As a direct consequence treatment with secukinumab reduces erythema, induration and desquamation present in plaque psoriasis lesions.
Croatian: Izravna je posljedica da liječenje sekukinumabom smanjuje eritem, zadebljanja i ljuštenje koji su prisutni kod lezija plak psorijaze.
English: After the first dose you will receive further weekly injections at weeks 1, 2, 3 and 4 followed by monthly injections.
Croatian: Nakon prve doze dobit ćete sljedeće tjedne injekcije u 1., 2., 3. i 4. tjednu nakon čega ćete dobivati mjesečne injekcije.
English: In psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies, less than 1% of patients treated with secukinumab developed antibodies to secukinumab up to 52 weeks of treatment.
Croatian: U kliničkim ispitivanjima psorijaze, psorijatičnog artritisa i ankilozantnog spondilitisa, manje od 1% bolesnika liječenih sekukinumabom razvilo je protutijela na sekukinumab do 52. tjedna liječenja.
English: Cosentyx is used to treat a skin condition called “plaque psoriasis”, which causes inflammation affecting the skin.
Croatian: Cosentyx se koristi za liječenje kožne bolesti koja se naziva „plak psorijaza“, a uzrokuje upalu koja zahvaća kožu.
English: For Psoriatic Arthritis study 3 (PsA study 3), the primary endpoint was at week 16 with the key secondary endpoint, the change from baseline in modified Total Sharp Score (mTSS), at week 24.
Croatian: Za 3. ispitivanje psorijatičnog artritisa (3. ispitivanje PsA), mjera primarnog ishoda bila je u 16. tjednu uz ključnu mjeru sekundarnog ishoda, promjenu u modificiranom ukupnom rezultatu po Sharpu (mTSS) u 24. tjednu, u odnosu na početnu vrijednost.
English: The resulting solution should be clear.
Croatian: Otopina koja nastane trebala bi biti bistra.
English: If possible, areas of the skin that show psoriasis should be avoided as injection sites.
Croatian: Ako je moguće, površinu kože zahvaćenu psorijatičnim promjenama kao mjesto primjene injekcije treba izbjegavati.
English: Detailed instructions for use are provided in the package leaflet.
Croatian: Detaljne upute za uporabu navedene su u uputi o lijeku.
English: The onset of action of secukinumab 150 mg occurred as early as week 1 for ASAS 20 and week 2 for ASAS 40 (superior to placebo) in AS study 2.
Croatian: Nastup djelovanja sekukinumaba 150 mg dogodio se već u 1. tjednu za ASAS 20 i 2. tjednu za ASAS 40 (superiorno u odnosu na placebo) u 2. ispitivanju AS-a.
English: Included in the carton:
Croatian: Uključeno u kutiju:
English: Patients randomised to etanercept received 50 mg doses twice per week for 12 weeks followed by 50 mg every week.
Croatian: Bolesnici randomizirani na etanercept primali su doze od 50 mg dvaput tjedno tijekom 12 tjedana, a nakon toga 50 mg svaki tjedan.
English: In clinical studies, urticaria and rare cases of anaphylactic reaction to secukinumab were observed (see also section 4.4).
Croatian: U kliničkim ispitivanjima uočena je urtikarija i rijetki slučajevi anafilaktičke reakcije na sekukinumab (vidjeti također dio 4.4).
English: In a study with secukinumab, infiltrating epidermal neutrophils and various neutrophil-associated markers that are increased in lesional skin of plaque psoriasis patients were significantly reduced after one to two weeks of treatment.
Croatian: U jednom ispitivanju sa sekukinumabom, infiltrirajući epidermalni neutrofili i razni markeri povezani s neutrofilima koji su povišeni kod kože s lezijama u bolesnika s plak psorijazom bili su značajno sniženi nakon jednog do dva tjedna liječenja.
English: Prior to use, a visual inspection of the pre-filled syringe is recommended.
Croatian: Prije uporabe preporučuje se vizualno pregledati napunjenu brizgalicu.
English: Secukinumab 300 mg was superior to placebo at week 12 as assessed by significant improvement from baseline in both the PSSI 90 response (52.9% versus 2.0%) and IGA mod 2011 0 or 1 scalp only response (56.9% versus 5.9%).
Croatian: Sekukinumab 300 mg bio je superioran u odnosu na placebo u 12. tjednu, procijenjeno značajnim poboljšanjem od početne vrijednosti kako u odgovoru PSSI 90 (52,9% u odnosu na 2,0%), tako i u odgovoru IGA mod 2011 0 ili 1 samo za vlasište (56,9% u odnosu na 5,9%).
English: In the placebo-controlled period of clinical studies in plaque psoriasis (a total of 1,382 patients treated with secukinumab and 694 patients treated with placebo for up to 12 weeks), infections were reported in 28.7% of patients treated with secukinumab compared with 18.9% of patients treated with placebo.
Croatian: U placebom kontroliranom razdoblju kliničkih ispitivanja plak psorijaze (ukupno 1382 bolesnika liječenih sekukinumabom i 694 bolesnika koji su primali placebo do 12 tjedana), infekcije su bile zabilježene u 28,7% bolesnika liječenih sekukinumabom u usporedbi s 18,9% bolesnika koji su primali placebo.
English: With the needle pointing upward, gently tap the syringe to move any air bubbles to the top.
Croatian: S iglom okrenutom prema gore, lagano kucnite po štrcaljki kako biste pomaknuli mjehuriće zraka, ako ih ima, na vrh.
English: Inhibition of progression of structural damage was also assessed in PsA study 1 at weeks 24 and 52, compared to baseline.
Croatian: Inhibicija progresije strukturalnog oštećenja ocijenjena je i u 1. ispitivanju PsA u 24. i 52. tjednu, u usporedbi s početnim vrijednostima.
English: In clinical studies, rare cases of anaphylactic reactions have been observed in patients receiving secukinumab.
Croatian: U kliničkim ispitivanjima opaženi su rijetki slučajevi anafilaktičkih reakcija u bolesnika koji su primali sekukinumab.
English: All p-values are adjusted for multiplicity of testing based on pre-defined hierarchy at week 16 for PsA study 3, except for ACR70 which was an exploratory endpoint and all endpoints at week 24.
Croatian: Sve p-vrijednosti prilagođene su za višestrukost testiranja na temelju unaprijed definirane hijerarhije u 16. tjednu za 3. ispitivanje PsA, osim za ACR70 koji je bio ekploratorna mjera ishoda te za sve mjere ishoda u 24. tjednu.
English: No interaction was seen when secukinumab was administered concomitantly with methotrexate (MTX) and/or corticosteroids in arthritis studies (including in patients with psoriatic arthritis and ankylosing spondylitis).
Croatian: Nisu opažene nikakve interakcije kada se sekukinumab primjenjivao istodobno s metotreksatom (MTX) i/ili kortikosteroidima u ispitivanjima artritisa (koja su uključivala bolesnike s psorijatičnim artritisom i ankilozantnim spondilitisom).
English: • Talk to your doctor if you are breast-feeding or are planning to breast-feed.
Croatian: • Obratite se svom liječniku ako dojite ili planirate dojiti.
English: Mean systemic clearance (CL) following a single intravenous administration to patients with plaque psoriasis ranged from 0.13 to 0.36 l/day.
Croatian: Srednji sistemski klirens (CL) nakon jednokratne intravenske primjene u bolesnika s plak psorijazom bio je u rasponu od 0,13 do 0,36 l/dan.
English: Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Croatian: Cosentyx je indiciran za liječenje umjerene do teške plak psorijaze u odraslih osoba koje su kandidati za sistemsku terapiju.
English: Table 1 List of adverse reactions in clinical studies and post-marketing experience
Croatian: Tablica 1 Popis nuspojava u kliničkim ispitivanjima i iz razdoblja nakon stavljanja lijeka u promet
English: Week 52 Placebo 150 mg 300 mg 150 mg 300 mg 150 mg 300 mg
Croatian: 52. tjedan Placebo 150 mg 300 mg 150 mg 300 mg 150 mg 300 mg
English: Secukinumab was administered concomitantly with methotrexate (MTX), sulfasalazine and/or corticosteroids in arthritis studies (including in patients with psoriatic arthritis and ankylosing spondylitis).
Croatian: Sekukinumab se istodobno primjenjivao s metotreksatom (MTX), sulfasalazinom i/ili kortikosteroidima u ispitivanjima artritisa (uključujući u bolesnika sa psorijatičnim artritisom i ankilozantnim spondilitisom).
English: As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases.
Croatian: Kao rezultat toga, sekukinumab inhibira otpuštanje proinflamatornih citokina, kemokina i medijatora oštećenja tkiva te smanjuje doprinose autoimunim i upalnim bolestima kojima posreduje IL-17A.
English: Cosentyx is used in adults with active ankylosing spondylitis.
Croatian: Cosentyx se koristi u odraslih osoba s aktivnim ankilozantnim spondilitisom.
English: Dactylitis resolution n (%) † Week 16
Croatian: Povlačenje daktilitisa n (%) † 16. tjedan
English: Treatment with secukinumab resulted in significant improvement in measures of disease activity compared to placebo at weeks 16 and 24 (see Table 5).
Croatian: Liječenje sekukinumabom rezultiralo je značajnim poboljšanjem u mjerama aktivnosti bolesti u usporedbi s placebom u 16. i u 24. tjednu (vidjeti Tablicu 5).
English: Based on your response, your doctor may increase your dose to 300 mg.
Croatian: Na temelju Vašeg odgovora, liječnik Vam može povećati dozu na 300 mg.
English: Related to the mechanism of action of secukinumab, non-serious mucocutaneous candida infections were more frequently reported for secukinumab than placebo in the psoriasis clinical studies (3.55 per 100 patient years for secukinumab 300 mg versus 1.00 per 100 patient years for placebo) (see section 4.8).
Croatian: Povezano s mehanizmom djelovanja sekukinumaba, mukokutane infekcije kandidom koje nisu bile ozbiljne bile su češće prijavljene uz sekukinumab nego uz placebo u kliničkim ispitivanjima psorijaze (3,55 na 100 bolesnik-godina uz sekukinumab 300 mg u odnosu na 1,00 na 100 bolesnik-godina uz placebo) (vidjeti dio 4.8).
English: Cosentyx is supplied in a colourless glass vial with a grey coated rubber stopper and aluminium cap with a white flip-off component containing 150 mg of secukinumab.
Croatian: Cosentyx se isporučuje u bočici bezbojnog stakla sa sivim obloženim gumenim čepom i aluminijskim poklopcem s bijelim „flip-off” dijelom koja sadrži 150 mg sekukinumaba.
English: If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of active psoriatic arthritis, improve physical function and slow down the damage to the cartilage and bone of the joints involved in the disease.
Croatian: Ako ne budete dovoljno dobro reagirali na te lijekove, dobit ćete Cosentyx za smanjivanje znakova i simptoma aktivnog psorijatičnog artritisa, poboljšanje tjelesne funkcije i usporavanje oštećenja hrskavice i kosti zglobova zahvaćenih bolešću.
English: Withdraw slightly more than 1.0 ml sterile water for injections into a 1 ml graduated disposable syringe and adjust to 1.0 ml.
Croatian: Izvucite malo više od 1,0 ml sterilne vode za injekcije u graduiranu štrcaljku od 1 ml za jednokratnu uporabu i podesite na 1,0 ml.
English: The single and multiple dose pharmacokinetics of secukinumab in plaque psoriasis patients were determined in several studies with intravenous doses ranging from 1x 0.3 mg/kg to 3x 10 mg/kg and with subcutaneous doses ranging from 1x 25 mg to multiple doses of 300 mg.
Croatian: Farmakokinetika jednokratnih i višestrukih doza sekukinumaba u bolesnika s plak psorijazom bila je utvrđena u nekoliko ispitivanja s intravenskim dozama u rasponu od 1x 0,3 mg/kg do 3x 10 mg/kg te sa supkutanim dozama u rasponu od 1x 25 mg do višestrukih doza od 300 mg.
English: In the anti-TNFα-IR patients subgroup, only the 300 mg dose showed significantly higher response rate for ACR 20 compared to placebo (p<0.05) and demonstrated clinical meaningful benefit over 150 mg on multiple secondary endpoints.
Croatian: U podskupini bolesnika s neodgovarajućim odgovorom na anti-TNFα, samo je doza od 300 mg pokazala značajno višu stopu odgovora za ACR 20 u usporedbi s placebo (p<0,05) i pokazala klinički značajnu korist u odnosu na 150 mg s obzirom na više mjera sekundarnog ishoda.
English: Live vaccines should not be given concurrently with secukinumab.
Croatian: Živa cjepiva ne smiju se davati istodobno sa sekukinumabom.
English: Using Cosentyx in psoriatic arthritis will benefit you by reducing the signs and symptoms of the disease, slowing down the damage to the cartilage and bone of the joints and improving your ability to do normal daily activities.
Croatian: Primjena Cosentyxa za psorijatični artritis koristit će Vam tako što će smanjiti znakove i simptome bolesti, usporiti oštećenje hrskavice i kosti zglobova i povećati Vašu sposobnost obavljanja uobičajenih svakodnevnih aktivnosti.
English: For detailed instructions on how to inject Cosentyx, see “Instructions for use of the Cosentyx SensoReady pen” at the end of this leaflet.
Croatian: Za detaljne upute o davanju injekcije Cosentyxa vidjeti „Upute za uporabu Cosentyx SensoReady brizgalice “ na kraju ove upute.
English: Instructions for reconstitution of Cosentyx 150 mg powder for solution for injection: Bring the vial of powder to room temperature and ensure that the sterile water for injections is at room temperature.
Croatian: Upute za rekonstituciju Cosentyx 150 mg praška za otopinu za injekciju: 1. Pustite da bočica s praškom dosegne sobnu temperaturu i osigurajte da je sterilna voda za injekcije sobne temperature.
English: Remove the syringe from the outer box and take it out of the blister.
Croatian: Izvadite štrcaljku iz kutije i blistera.
English: Holding your pen: • Hold the pen at 90 degrees to the cleaned injection site.
Croatian: • Držite brizgalicu pod kutem od 90 stupnjeva u odnosu na očišćeno mjesto primjene.
English: In PsA study 1 and PsA study 2, efficacy was maintained up to week 104.
Croatian: U 1. i 2. ispitivanju PsA djelotvornost se održala do 104. tjedna.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Cosentyx in plaque psoriasis in paediatric patients aged from birth to less than 6 years and in chronic idiopathic arthritis for paediatric patients aged from birth to less than 2 years (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Cosentyx za plak psorijazu u pedijatrijskih bolesnika u dobi od rođenja do manje od 6 godina i za kronični idiopatski artritis za pedijatrijske bolesnike u dobi od rođenja do manje od 2 godine (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Vials are for single use only.
Croatian: Bočice su namijenjene za jednokratnu uporabu.
English: For detailed instructions on how to inject Cosentyx, see “Instructions for use of Cosentyx pre-filled syringe” at the end of this leaflet.
Croatian: Za detaljne upute o davanju injekcije Cosentyxa vidjeti „Upute za uporabu Cosentyx napunjene štrcaljke“ na kraju ove upute.
English: Cosentyx is supplied in a single-use pre-filled syringe assembled into a triangular-shaped pen with transparent window and label.
Croatian: Cosentyx se isporučuje u napunjenoj štrcaljki za jednokratnu uporabu postavljenoj u brizgalici trokutastog oblika s prozirnim prozorčićem i naljepnicom.
English: For the participants completing the diary in each of these studies, statistically significant improvements at week 12 from baseline compared to placebo in patient-reported signs and symptoms of itching, pain and scaling were demonstrated.
Croatian: Za ispitanike koji su ispunjavali dnevnik u svakom od ovih ispitivanja dokazana su statistički značajna poboljšanja u 12. tjednu u odnosu na početnu vrijednost u usporedbi s placebom u znakovima i simptomima svrbeža, boli i ljuštenja koje su prijavili bolesnici.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Cosentyx in plaque psoriasis in paediatric patients aged from 6 years to less than 18 years and in chronic idiopathic arthritis for paediatric patients aged from 2 years to less than 18 years (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka Cosentyx za plak psorijazu u pedijatrijskih bolesnika u dobi od 6 godina do manje od 18 godina i za kronični idiopatski artritis za pedijatrijske bolesnike u dobi od 2 godine do manje od 18 godina (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: For Psoriatic Arthritis study 1 (PsA study 1) and Psoriatic Arthritis study 2 (PsA study 2), the primary endpoint was at week 24.
Croatian: Za 1. ispitivanje psorijatičnog artritisa (1. ispitivanje PsA) i 2. ispitivanje psorijatičnog artritisa (2. ispitivanje PsA), mjera primarnog ishoda bila je u 24. tjednu.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP BLISTER NAPUNJENE ŠTRCALJKE
English: Table 5 Clinical response in PsA study 2 and PsA study 3 at week 16 and week 24
Croatian: Tablica 5 Klinički odgovor u 2. i 3. ispitivanju PsA u 16. i u 24. tjednu
English: Table 2 Summary of PASI 50/75/90/100 & IGA mod 2011 “clear” or “almost clear” clinical response in psoriasis studies 1, 3 and 4 (ERASURE, FEATURE and JUNCTURE)
Croatian: Tablica 2 Sažetak kliničkih odgovora PASI 50/75/90/100 i IGA mod 2011 „čista“ ili „gotovo čista“ u 1., 3. i 4. ispitivanju psorijaze (ERASURE, FEATURE i JUNCTURE)
English: Cosentyx is to be administered by subcutaneous injection.
Croatian: Cosentyx se treba primijeniti supkutanom injekcijom.
English: Statistically significant improvements at week 4 from baseline in patients treated with secukinumab compared to patients treated with ustekinumab (CLEAR) were demonstrated in the DLQI and these improvements were maintained for up to 52 weeks.
Croatian: Statistički značajna poboljšanja u 4. tjednu u odnosu na početnu vrijednost u bolesnika liječenih sekukinumabom u usporedbi s bolesnicima liječenim ustekinumabom (CLEAR) dokazana su korištenjem DLQI-ja i održala su se do 52 tjedna.
English: Table 7 Clinical response in AS study 2 at week 16
Croatian: Tablica 7 Klinički odgovor u 2. ispitivanju AS-a u 16. tjednu
English: If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of the disease, reduce inflammation and improve your physical function.
Croatian: Ako ne budete dovoljno dobro reagirali na te lijekove, dobit ćete Cosentyx za smanjivanje znakova i simptoma bolesti, smanjivanje upale i poboljšanje tjelesne funkcije.
English: If you forget to use Cosentyx
Croatian: Ako ste zaboravili primijeniti Cosentyx
English: Cosentyx SensoReady pen 150 mg
Croatian: Cosentyx SensoReady brizgalica 150 mg
English: Solution for injection in pre-filled pen (SensoReady pen)
Croatian: Otopina za injekciju u napunjenoj brizgalici (SensoReady brizgalici)
English: If you think you may be allergic, ask your doctor for advice before using Cosentyx.
Croatian: Ako mislite da biste mogli biti alergični, upitajte svog liječnika za savjet prije nego što primijenite Cosentyx. ako imate aktivnu infekciju za koju Vaš liječnik smatra da je važna.
English: Tilt the vial to an angle of approx. 45° and gently rotate between the fingertips for approx. 1 minute.
Croatian: 7. Nagnite bočicu pod kutem od otprilike 45° i nježno je rotirajte između prstiju otprilike 1 minutu.
English: Based on population pharmacokinetic analysis, following a single subcutaneous dose of either 150 mg or 300 mg in plaque psoriasis patients, secukinumab reached peak serum concentrations of 13.7±4.8 µg/ml or 27.3±9.5 µg/ml, respectively, between 5 and 6 days post dose.
Croatian: Na temelju populacijske farmakokinetičke analize, nakon jednokratne supkutane doze od 150 mg ili 300 mg u bolesnika s plak psorijazom, sekukinumab je dosegao vršne koncentracije u serumu od 13,7±4,8 µg/ml odnosno 27,3±9,5 µg/ml, između 5 i 6 dana nakon doze.
English: • upper respiratory tract infections with symptoms such as sore throat and stuffy nose
Croatian: • infekcije gornjeg dijela dišnog sustava sa simptomima kao što su grlobolja i začepljen nos
English: If you stop using Cosentyx
Croatian: Ako prestanete primjenjivati Cosentyx
English: Cosentyx is available in packs containing one vial.
Croatian: Cosentyx je dostupan u pakiranjima koja sadrže jednu bočicu.
English: The safety and efficacy of secukinumab were assessed in four randomised, double-blind, placebo-controlled phase III studies in patients with moderate to severe plaque psoriasis who were candidates for phototherapy or systemic therapy [ERASURE, FIXTURE, FEATURE, JUNCTURE].
Croatian: Sigurnost i djelotvornost sekukinumaba ocjenjivali su se u četiri randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja faze III u bolesnika s umjerenom do teškom plak psorijazom koji su bili kandidati za fototerapiju ili sistemsku terapiju [ERASURE, FIXTURE, FEATURE, JUNCTURE].
English: Live vaccines should not be given concurrently with secukinumab (see also section 4.4).
Croatian: Živa cjepiva ne smiju se davati istodobno sa sekukinumabom (vidjeti također dio 4.4).
English: Important safety checks before you inject:
Croatian: Važne sigurnosne provjere prije nego što si date injekciju: Tekućina treba biti bistra.
English: No natural rubber latex has to date been detected in the removable cap.
Croatian: Do danas u poklopcu nije pronađen prirodni gumeni lateks.
English: Choose a different site each time an injection is administered.
Croatian: Odaberite drugo mjesto svaki put kad primjenjujete injekciju.
English: • burning sensation when passing urine.
Croatian: • osjećaj peckanja pri mokrenju.
English: Instructions for use of Cosentyx powder for solution for injection
Croatian: Upute za uporabu Cosentyx praška za otopinu za injekciju
English: The majority of infections consisted of non-serious and mild to moderate upper respiratory tract infections, such as nasopharyngitis, which did not necessitate treatment discontinuation.
Croatian: Većina infekcija sastojala se od blagih do umjerenih infekcija gornjeg dijela dišnog sustava koje nisu bile ozbiljne, kao što je nazofaringitis, zbog kojih nije bilo potrebno prekinuti liječenje.